07Jun 2021
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study

Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. In this randomized, open‐label, interventional study, we included 61 postmenopausal women and men older than 50 years discontinuing denosumab after 4.6 ± 1.6 years.

  • #orthopaedics

Like

Save

Share